Marcie A. Goldstein

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with the $100.3 million initial public offering of 7,187,500 shares of common stock of Oportun Financial Corporation, of which 4,873,356…

Davis Polk advised the underwriters in connection with the $648 million initial public offering by Datadog, Inc. of 24,000,000 shares of its Class A common stock. The Class A common stock…

Davis Polk advised the joint book-running managers in connection with the $162.4 million SEC-registered follow-on offering of 2,680,089 shares of Class A common stock of Hamilton Lane…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies, Inc…

Davis Polk advised the underwriters in connection with a $202.5 million public offering of common stock by Turning Point Therapeutics, Inc. Turning Point Therapeutics’ common stock is…

Davis Polk advised the sole bookrunner in connection with the SEC-registered offering of 2,329,000 shares of Class A common stock of Appian Corporation by Appian and certain existing…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…

Davis Polk advised the underwriters on the SEC-registered initial public offering by 9F Inc. of 8,900,000 American Depositary Shares, consisting of 6,750,000 ADSs sold by 9F and 2,150,000…

Davis Polk advised the sole bookrunner in connection with the $168 million SEC-registered secondary offering of 12,000,000 shares of Class A common stock of Hostess Brands, Inc. by certain…